Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Collaboration
Friday, March 10, 2023
Alnylam Pharmaceuticals and Medison Pharma ("Medison”) announced an expansion of the existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.
This new agreement builds upon the successful long-term partnership between Alnylam and Medison in Israel and will allow Alnylam to utilise Medison's unique multi-regional platform to ensure that Alnylam's innovative RNA interference (RNAi) therapeutics, such as ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) are made available across additional countries in Europe. This expanded agreement is intended to ensure more efficient and effective commercialisation. GIVLAARI® and OXLUMO® have already been approved for reimbursement in Poland, and Alnylam and Medison will work together to obtain additional reimbursements in the territories.
The expansion of the existing relationship with Medison, will allow to strengthen the presence and bring the benefits of Alnylam's innovative RNAi therapies to patients in Central and Eastern Europe.
